Hematology and Oncology Book

Tranfusion

http://www.fpnotebook.com/

Antiplatelet Management in Diabetes Mellitus

Aka: Antiplatelet Management in Diabetes Mellitus, Aspirin Use in Diabetes
  1. See Also
    1. Antiplatelet Therapy for Vascular Disease
  2. Background
    1. Aspirin has historically been considered in all diabetic patients or starting at age 45 years in men and age 55 years in women
  3. Indications: Low dose Aspirin 81 mg daily (more specific as of 2012)
    1. Framingham risk >10%, no vascular disease, and no Bleeding Diathesis
    2. Males over age 50 years or females over age 60 years and
    3. One additional Cardiovascular Risk Factor
      1. Tobacco abuse
      2. Hypertension
      3. Dyslipidemia
      4. Albuminuria
      5. Family History of premature cardiovascular death
  4. Indications: Clopidogrel (Plavix) 75 mg daily
    1. Known cardiovascular disease
  5. Adverse Effects
    1. See Aspirin
    2. Aspirin does not increase risk of Retinal Hemorrhage

Antiplatelet therapy (C1096021)

Concepts Therapeutic or Preventive Procedure (T061)
Italian Terapia antipiastrinica
Japanese 抗血小板療法, コウケッショウバンリョウホウ
Czech Antiagregační léčba
English antiplatelet therapy, Antiplatelet therapy
Hungarian Thrombocyta-gátló kezelés
Portuguese Tratamento anti-plaquetas
Spanish Tratamiento antiplaquetario
Dutch antibloedplaatjestherapie
French Traitement antiplaquettaire
German Therapie mit Thrombozytenaggregationshemmer
Sources
Derived from the NIH UMLS (Unified Medical Language System)


You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree